Acceleron Pharma (XLRN) Misses Q1 EPS by 15c, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. SPCX
2. HUM
3. ALHC
4. T
5. PEP
6. UNH
7. CVS
8. SBUX
9. AXP
10. ZETA

Go back to Acceleron Pharma (XLRN) Misses Q1 EPS by 15c, Revenues Miss

Acceleron Reports First Quarter 2019 Operating and Financial Results

May 9, 2019 4:05 PM EDT

Luspatercept Biologics License Application (BLA) and Marketing Authorization Application (MAA) submitted in April 2019

Part 2 results from the ACE-083 Phase 2 trials in facioscapulohumeral muscular dystrophy (FSHD) expected in the second half of 2019 and Charcot-Marie-Tooth disease (CMT) anticipated in Q1 2020

PULSAR and SPECTRA Phase 2 trials of sotatercept in pulmonary arterial hypertension (PAH) on track with topline results expected from PULSAR in 1H 2020

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics... More